Last Updated: November 17, 2026

Details for Patent: 9,926,559

« Back to Dashboard


Which drugs does patent 9,926,559 protect, and when does it expire?

Patent 9,926,559 protects SPINRAZA and is included in one NDA.

This patent has two patent family members in two countries.

Summary for Patent: 9,926,559
Title:Compositions and methods for modulation of SMN2 splicing in a subject
Abstract:Disclosed herein are compounds, compositions and methods for modulating splicing of SMN2 mRNA in a subject. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders, including spinal muscular atrophy.
Inventor(s):C. Frank Bennett, Gene Hung, Frank Rigo
Assignee: Biogen MA Inc
Application Number:US14/760,171
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,926,559
Patent Claim Types:
see list of patent claims
Use;
Patent landscape, scope, and claims:

US Patent 9,926,559: Nusinersen Patent Scope, Expiration, Orange Book Status, and Generic Entry Risk

US Patent 9,926,559 protects a narrow but commercially important method of administering nusinersen, marketed as Spinraza. The patent covers the 18-nucleotide antisense oligonucleotide sequence, its 2'-MOE and phosphorothioate chemistry, intrathecal bolus delivery, specified dose levels, age-based administration volumes, needle gauges, lumbar injection location, and an initial repeat dose 12 to 18 days later.

The patent is assigned to Ionis Pharmaceuticals and is part of the Spinraza patent estate licensed to Biogen. Its nominal patent term extends to June 5, 2034, subject to any applicable patent-term adjustment, terminal-disclaimer restrictions, or other USPTO corrections. FDA approval of Spinraza occurred on December 23, 2016, and the product also received orphan-drug exclusivity and pediatric exclusivity. [1-4]

What drug does US Patent 9,926,559 protect?

US 9,926,559 protects a treatment method using nusinersen, an antisense oligonucleotide directed against the SMN2 pre-mRNA transcript.

The claimed oligonucleotide has these defining characteristics:

Claim element Required limitation
Therapeutic indication Human spinal muscular atrophy
Molecule 18-linked-nucleoside antisense oligonucleotide
Sequence SEQ ID NO:1, corresponding to the nusinersen targeting sequence
Internucleoside chemistry Every linkage is phosphorothioate
Sugar chemistry Every nucleoside is 2'-MOE
Cytosine chemistry Every cytosine is 5-methyl cytosine
Route Cerebrospinal-fluid administration
Delivery method Bolus injection into the intrathecal space
Dose 9.6, 10.3, 10.8, 11.3, or 12.0 mg

The patent does not broadly cover every antisense treatment for SMA. It requires the claimed sequence and chemistry in combination with intrathecal dosing at one of the stated dose levels.

Nusinersen binds to an intronic splicing silencer region in SMN2 pre-mRNA. The treatment promotes inclusion of exon 7, increasing production of full-length survival motor neuron protein. The mechanism distinguishes nusinersen from risdiplam, a small-molecule SMN2 splicing modifier, and onasemnogene abeparvovec, an AAV-based gene-replacement therapy.

What are the independent and dependent claim limitations?

Claim 1 is the principal enforceable method claim. It requires proof of every limitation.

A party practices claim 1 only if it:

  1. Treats a human subject with SMA.
  2. Administers the specific 18-nucleotide sequence.
  3. Uses the claimed 2'-MOE, phosphorothioate, 5-methylcytosine configuration.
  4. Delivers the drug intrathecally into cerebrospinal fluid by bolus injection.
  5. Administers one of the five specified doses.

The dependent claims narrow the administration procedure.

Claim Additional limitation
2 Needle gauge of 21, 22, 23, 24, or 25
3 22-gauge needle
4 Injection between L3 and L4 vertebrae
5 9.6 mg in 4 mL, within three months of birth
6 10.3 mg in 4.3 mL, between three and six months after birth
7 10.8 mg in 4.5 mL, between six and 12 months after birth
8 11.3 mg in 4.7 mL, between 12 and 24 months after birth
9 12.0 mg in 5 mL, after 24 months of birth
10 At least two doses, with the second dose 12 to 18 days after the first

Claim 10 is directed to the early loading regimen. The 12-to-18-day interval overlaps the approximately two-week repeat dosing used in the initial Spinraza loading schedule.

How broad is the scope of US 9,926,559?

The patent has strong literal coverage of the approved Spinraza regimen but limited coverage outside that regimen.

Sequence and chemistry limitations

The sequence limitation sharply narrows the claim. A competing antisense oligonucleotide with a different sequence would not literally satisfy claim 1, even if it targeted SMN2 and produced the same biological effect.

The chemistry limitations are also cumulative. The claimed compound must have:

  • 2'-MOE sugar modifications at every nucleoside;
  • phosphorothioate linkages at every internucleoside position; and
  • 5-methylcytosine at every cytosine position.

A molecule using phosphodiester linkages, phosphorodiamidate morpholino chemistry, constrained ethyl chemistry, 2'-O-methyl substitutions, or an alternative cytosine modification would fall outside the literal wording of claim 1.

Dose and route limitations

The claim does not cover every intrathecal dose of nusinersen. It specifies five discrete dose levels. A 12.1 mg dose or a materially different dosing regimen would not literally meet the stated dose limitation.

The route requirement is also specific. Intravenous, subcutaneous, intramuscular, epidural, or oral delivery would not satisfy the claim. Intrathecal administration into the cerebrospinal-fluid compartment is central to the patent.

Method-of-treatment limitations

The patent is a method patent, not a composition patent. It generally requires evidence that the accused party administered the claimed product to a human SMA patient. Manufacture, sale, or possession of nusinersen may implicate other patents, regulatory provisions, or contributory-infringement theories, but those activities do not automatically satisfy the treatment steps in claim 1.

What patent protects the nusinersen sequence and composition?

US 9,926,559 is one component of the broader nusinersen estate. Earlier Ionis patents cover the antisense sequence, SMN2 modulation, oligonucleotide compositions, and therapeutic use more generally.

The foundational estate includes patents directed to:

  • antisense modulation of SMN2 expression;
  • the nusinersen sequence and related antisense compounds;
  • 2'-MOE phosphorothioate oligonucleotides;
  • methods of treating SMA;
  • intrathecal administration; and
  • dosing regimens for pediatric and adult patients.

US Patent 8,980,853, titled "Antisense modulation of survival motor neuron 2 expression," is commonly identified as a foundational Spinraza patent. US 9,926,559 adds regimen-specific protection, particularly the intrathecal doses and age-based administration volumes. [5]

The commercial effect is cumulative. A generic or follow-on developer may need to avoid several patents rather than design around US 9,926,559 alone.

When does US Patent 9,926,559 lose exclusivity?

The nominal expiration date is June 5, 2034.

Event Date or status
Patent grant March 27, 2018
FDA approval of Spinraza December 23, 2016
Five-year new chemical entity exclusivity Ended in December 2021
Seven-year orphan-drug exclusivity Ended in December 2023
Six-month pediatric extension May extend applicable FDA exclusivity into 2024, depending on exclusivity calculation
Nominal patent expiration June 5, 2034

FDA regulatory exclusivity and patent protection are separate. The end of orphan or pediatric exclusivity did not eliminate the patent barrier. A generic applicant could potentially file an ANDA after the relevant statutory filing period, but commercial launch would remain subject to listed patents and any litigation stay.

What is the Orange Book status of Spinraza?

Spinraza is approved under NDA 209531. Biogen is the commercial sponsor, while Ionis is the originator of the antisense technology and a key patent holder or licensor.

The Orange Book identifies patent protection for approved drug products through patent-number and use-code listings. Spinraza's listed protection is relevant to abbreviated new drug applications that rely on the Spinraza reference product. A generic applicant may make:

  • a Paragraph III certification, accepting delay until patent expiration;
  • a Paragraph IV certification, asserting that a listed patent is invalid, unenforceable, or not infringed; or
  • a section viii statement, carving out a patented method of use where the remaining label supports approval.

US 9,926,559 is particularly relevant to a generic label that includes the patented intrathecal dosing regimen. A section viii carve-out could be difficult if the approved generic labeling necessarily reproduces the same dose and loading instructions.

FDA Orange Book treatment does not determine ultimate patent validity. It determines the regulatory consequences of a certification and can trigger the 30-month stay under the Hatch-Waxman framework if the NDA holder or patent owner files an infringement action within the statutory period. [1,6]

Have generic companies filed Paragraph IV challenges to Spinraza?

No publicly established Paragraph IV litigation record is identified for US 9,926,559 in the materials supporting this analysis.

That does not eliminate future challenge risk. The principal challenge window would arise when an ANDA applicant seeks approval for a nusinersen product and certifies against the listed Spinraza patents. The likely dispute would focus on:

  • whether the proposed product has the identical sequence and modification pattern;
  • whether the proposed label induces the patented method;
  • whether dose or administration changes avoid literal infringement;
  • whether the patent claims are anticipated or obvious;
  • whether the specification adequately supports the precise dose and volume combinations; and
  • whether the patent is enforceable in view of prosecution conduct.

A Paragraph IV case would likely involve US 9,926,559 together with earlier composition and SMN2 patents. The commercial risk would therefore depend on the entire Orange Book estate, not this patent in isolation.

How strong is the patent estate for Spinraza?

US 9,926,559 has high literal-infringement strength against a conventional generic that copies the Spinraza label and product characteristics.

Its principal strengths are:

  • precise correspondence to the approved drug;
  • detailed chemical limitations;
  • exact intrathecal route;
  • defined dose levels;
  • age-based dosing volumes; and
  • a loading-dose interval that tracks clinical use.

Its principal vulnerabilities are claim narrowness and potential validity challenges. A challenger could argue that the selected doses and administration parameters would have been obvious in view of earlier SMA antisense studies, clinical protocols, or routine dose optimization. The patent owner would counter that the claimed combinations reflect specific clinical development work and are not merely arbitrary selections.

The patent is stronger against an identical generic regimen than against a modified regimen. A product using the same nusinersen sequence but a different dose may avoid claim 1 while remaining exposed to other patents or infringement theories.

What formulation and manufacturing patents affect generic entry?

US 9,926,559 does not primarily claim a formulation. It claims treatment using a chemically defined oligonucleotide and specifies administration volumes in dependent claims.

Generic entry may still face separate barriers involving:

  • oligonucleotide synthesis and purification;
  • control of stereochemistry and phosphorothioate distribution;
  • impurity profiles;
  • stability and container systems;
  • sterile injectable manufacturing;
  • analytical characterization;
  • bioequivalence and pharmacokinetic comparability; and
  • manufacturing-process patents.

For an antisense oligonucleotide, regulatory similarity may require extensive analytical data because conventional small-molecule bioequivalence methods do not fully capture sequence identity, impurity profile, chain-length distribution, and chemical substitution patterns. These manufacturing issues are not automatically covered by US 9,926,559, but they can increase the practical cost and timing of generic development.

What licensing deal controls Spinraza commercialization?

Ionis and Biogen entered into a collaboration covering nusinersen development and commercialization. Biogen obtained rights to develop and commercialize Spinraza globally, while Ionis retained economic participation through upfront consideration, milestone payments, and royalties.

The collaboration made Biogen the principal regulatory and commercial counterparty for Spinraza, while Ionis remained central to the underlying antisense technology and patent position. [7]

This structure matters in litigation and licensing because a generic challenge may involve both the NDA holder and patent owner. It also affects settlement authority, royalty economics, and allocation of enforcement responsibilities.

How does Spinraza compare with competing SMA drugs?

Product Active technology Sponsor Administration Main competitive issue
Spinraza Nusinersen antisense oligonucleotide Biogen/Ionis Intrathecal injection Procedure burden and repeat dosing
Evrysdi Risdiplam small molecule Roche/Genentech Oral or enteral administration Convenience and chronic dosing
Zolgensma Onasemnogene abeparvovec gene therapy Novartis One-time intravenous infusion High upfront cost and gene-therapy eligibility
Qalsody Tofersen antisense oligonucleotide Biogen/Ionis Intrathecal injection ALS indication, not general SMA competition

Spinraza retains a distinct patent position because its protection combines a defined antisense sequence with a specific intrathecal clinical regimen. Evrysdi and Zolgensma compete therapeutically but do not directly avoid or invalidate the nusinersen claims merely by using different modalities.

What generic launch scenarios exist?

The most plausible launch scenarios are:

  1. A generic copies the sequence, chemistry, dose, and intrathecal label and challenges the listed patents under Paragraph IV.
  2. A follow-on product changes dose, volume, or loading interval to avoid US 9,926,559 while confronting earlier composition and method patents.
  3. An applicant seeks a section viii carve-out for patented dosing instructions, although this may be difficult because intrathecal dosing is central to the product's approved use.
  4. A product launches after patent expiry, subject to any patent-term adjustment or enforceable related patents.
  5. A settlement permits an agreed launch date before the nominal June 2034 expiration.

The first scenario carries the highest litigation exposure. The second reduces exposure to this patent but may not provide freedom to operate across the full Spinraza estate.

Key Takeaways

  • US 9,926,559 is a narrow method-of-treatment patent centered on the Spinraza regimen.
  • Claim 1 requires the exact nusinersen sequence, 2'-MOE chemistry, phosphorothioate linkages, 5-methylcytosines, intrathecal bolus delivery, and one of five specified doses.
  • Claims 5 through 9 protect age-based dose-volume combinations.
  • Claim 10 protects the initial repeat dose administered 12 to 18 days after the first dose.
  • The nominal expiration date is June 5, 2034.
  • The patent is stronger against an identical generic label than against a modified regimen.
  • Generic developers must assess the full Ionis-Biogen patent estate, including foundational SMN2 and composition patents.
  • No established Paragraph IV litigation record is identified for this patent in the cited materials.
  • Spinraza's FDA exclusivity periods have expired or substantially expired, but patent protection remains the principal long-term barrier.
  • The principal commercial alternatives are Evrysdi and Zolgensma, which use different therapeutic modalities.

FAQs

Does US 9,926,559 cover all nusinersen products?

No. It covers a specific chemical configuration and specified intrathecal SMA treatment regimen. Other nusinersen products may still face separate patents.

Can a generic avoid US 9,926,559 by changing the injection needle?

Changing the needle could avoid claims 2 and 3, but it would not avoid claim 1. The generic would need to avoid the independent claim or invalidate it.

Does a different intrathecal dose avoid the patent?

A materially different dose may avoid the literal dose limitation in claim 1, but other Spinraza patents could still apply.

Is US 9,926,559 a composition patent?

No. It is principally a method patent. The claimed subject matter is the treatment of a human SMA patient using a defined antisense oligonucleotide and administration regimen.

Does the patent cover risdiplam or gene therapy for SMA?

No. Risdiplam is a small molecule, and onasemnogene abeparvovec is an AAV gene therapy. Neither product satisfies the claimed nusinersen oligonucleotide limitations.

References

  1. U.S. Food and Drug Administration. (2016). Spinraza (nusinersen) prescribing information.
  2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
  3. United States Patent and Trademark Office. (2018). U.S. Patent No. 9,926,559, methods of treating spinal muscular atrophy.
  4. United States Patent and Trademark Office. (2015). U.S. Patent No. 8,980,853, antisense modulation of survival motor neuron 2 expression.
  5. Ionis Pharmaceuticals, Inc., & Biogen Inc. (2012). Collaboration and license agreement relating to antisense therapeutics for spinal muscular atrophy.
  6. U.S. Food and Drug Administration. (2023). Hatch-Waxman amendments: Patent certifications and statutory exclusivity provisions.
  7. Biogen Inc. (2016). Spinraza approval and commercialization materials.

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 9,926,559

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Biogen SPINRAZA nusinersen sodium SOLUTION;INTRATHECAL 209531-001 Dec 23, 2016 RX Yes Yes 9,926,559 ⤷  Start Trial TREATMENT OF SPINAL MUSCULAR ATROPHY ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 9,926,559

PCT Information
PCT FiledJanuary 09, 2014PCT Application Number:PCT/US2014/010930
PCT Publication Date:July 17, 2014PCT Publication Number: WO2014/110291

International Family Members for US Patent 9,926,559

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 2943225 ⤷  Start Trial
World Intellectual Property Organization (WIPO) 2014110291 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.